High frequency of activating PIK3CA mutations in human papillomavirus - Positive oropharyngeal cancer

JAMA Otolaryngology - Head and Neck Surgery

Volumn 139, Issue 6, 2013, Pages 617-622

  Nichols, Anthony C ^a,b,c   Palma, David A ^a,b,c   Chow, Winsion ^a   Tan, Susan ^a   Rajakumar, Chandheeb ^a   Rizzo, Giananthony ^b   Fung, Kevin ^a,b   Kwan, Keith ^a   Wehrli, Brett ^a   Winquist, Eric ^a,b   Koropatnick, James ^a,b,c   Mymryk, Joe S ^a,b,c   Yoo, John ^a,b   Barrett, John W ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; ARTICLE; BIOPSY; CODON; CONTROLLED STUDY; ENZYME ACTIVE SITE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS POSITIVE OROPHARYNGEAL CANCER; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION; ONCOGENE; OROPHARYNX CANCER; OUTCOME ASSESSMENT; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; WART VIRUS;

BIOPSY; CODON; FEMALE; HUMANS; MALE; MUTATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PHOSPHATIDYLINOSITOL 3-KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84879334206     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.3210     Document Type: Article

References (17)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol . 2011;29(32):4294-4301.
2. Haigentz M Jr, Silver CE, Corry J, et al. Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol. 2009;266(12):1845-1855.
3. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582-3589.
4. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154-1157.
5. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-1160.
6. Nichols AC, Dhaliwal SS, Palma DA, et al. HPV as a prognostic factor in oropharyngeal cancer: does HPV type matter? J Otolaryngol Head Neck Surg. 2013;42:9.
7. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAFmutant cancer. Nat Rev Drug Discov. 2012;11(11):873-886.
8. Kozaki K, Imoto I, Pimkhaokham A, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 2006;97(12):1351-1358. (Pubitemid 44614987)
9. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol. 2008;32(1):101-111. (Pubitemid 351176067)
10. Suda T, Hama T, Kondo S, et al. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer. 2012;12(1):416.
11. Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov. 2011;10(8):563-564.
12. Henken FE, Banerjee NS, Snijders PJ, et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol Cancer. 2011;10:71.
13. Xu J, He J, Yang H, et al. Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark. 2011-2012;10(2):63-69.
14. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
15. Huang SH, Perez-Ordonez B, Weinreb I, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49(1):79-85.
16. Hausman D. Phase 1 and 2 study of PX-866 and cetuximab. http://www.clinicaltrials.gov/ct2/show/NCT01252628. Accessed November 1, 2012.
17. Study of PX-866 and docetaxel in solid tumors. http://www.clinicaltrials. gov/ct2/show/NCT01204099. Accessed November 1, 2012.